195
Participants
Start Date
May 31, 2003
Primary Completion Date
July 31, 2007
ICL670, deferoxamine
Weill Medical College of Cornell University, New York
Sickle Cell Center, Montefiore Hospital, The Bronx
NY Methodist Hospital, Brooklyn
U. Of Rochester Medical Center, Rochester
Children's Hospital of Pittsburgh, Pittsburgh
Penn State Milton S Hershey Medical Center, Hershey
Children's Hospital of Philadelphia, Philadelphia
Howard University Hospital, Washington D.C.
Children's Hospital of the King's Daughter, Norfolk
Wake Forest University School of Medicine, Winston-Salem
Santee Hematology/Oncology, Sumter
Liberty Hematology Oncology Center, Columbia
Palmetto Health Clinical Trials, Columbia
Georgia Comprehensive Sickle cell Center, Grady Hospital, Atlanta
Adult Sickle Cell Clinic, Medical College of Georgia, Augusta
Tampa Children's Hospital at St Joseph's, Tampa
U. of S. Alabama Medical Center, Mobile
James Cancer Hospital, Columbus
Barrett Center, University of Cincinnati, Cincinnati
Children's Hospital Medical Center, Cincinnati
Karmanos Cancer Institute, Detroit
University of Illinois at Chicago, Chicago
Children's Memorial Hospital, Chicago
Tulane University Sickle Cell Center, New Orleans
Children's Hospital, Department of Hematology/Oncology, New Orleans
Scott and White Memorial Hospital & Clinics, Temple
Baylor College of Medicine, Houston
Texas Children's Hospital/Baylor College of Medicine, Houston
Colorado Sickle Cell Treatment and Research Center, Denver
Children's Hospital Los Angeles, Los Angeles
Loma Linda University Medical Center, Loma Linda
Children's Hospital & Research Center, Oakland
Children's Hospital Boston, Division of Hematology/Oncology, Boston
Boston Medical Center, Boston
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY